

UCB S.A.

[View the current UCB S.A. Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/10406-UCB+S.A..html)

(<http://www.bioportfolio.com/biocorporate/10406-UCB+S.A..html>)

Contact Details:

Alle de la Recherche, 60
Brussels

Tel: +32/2/559.99.99

Fax: +32/2/559.99.00

Email: sally.miller@ucb-group.com

1070

Belgium

UCB is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. **Vision** To build a global biopharmaceutical leader, based on unique blending of innovation, entrepreneurship and proven experience bringing to specialists first, new medicines to treat patients suffering from severe diseases.

Recent Publications by UCB S.A.:



- [Visualization of SV2A conformations in situ by the use of Protein Tomography.](#)
*The synaptic vesicle protein 2A (SV2A), the brain-binding site of the...*28th October, 2008
Department of Molecular and Cellular Sciences, UCB S.A., Granta Park,- Biochem Biophys Res Commun. 2008 Oct 31;375(4):491-5. Epub 2008 Aug 8. ([DOI Direct Link](#))
- [2,6-Quinolinylnyl derivatives as potent VLA-4 antagonists.](#)
*A new series of 2,6-quinolinylnyl derivatives was prepared leading to potent...*25th April, 2007
UCB S.A., R&D, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium.- Bioorg Med Chem Lett. 2007 Jan 1;17(1):142-6. Epub 2006 Oct 10. ([DOI Direct Link](#))
- [Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies.](#)
*High-throughput screening of the UCB sample collection identified the...*25th April, 2007
CNS Molecular and Cellular Biology, Centre for CNS Innovation, UCB S.A.,- Bioorg Med Chem Lett. 2007 Jan 1;17(1):272-7. Epub 2006 Oct 5. ([DOI Direct Link](#))

- [The connexin 36 blockers quinine, quinidine and mefloquine inhibit cortical spreading depression in a rat neocortical slice model in vitro.](#)
A protocol for inducing cortical spreading depression (SD) on rat... 3rd February, 2007
 UCB S.A., CNS Research, B-1420 Braine-l'Alleud, Belgium.- Brain Res Bull. 2006 Dec 11;71(1-3):23-8. Epub 2006 Aug 11. ([DOI Direct Link](#))
- [Binding characteristics of levetiracetam to synaptic vesicle protein 2A \(SV2A\) in human brain and in CHO cells expressing the human recombinant protein.](#)
A specific binding site for the antiepileptic drug levetiracetam... 26th July, 2006
 UCB S.A., CNS Research, Chemin du Foriest, 1420 Braine L'Alleud, Belgium.- Eur J Pharmacol. 2006 Apr 24;536(1-2):102-8. Epub 2006 Mar 10. ([DOI Direct Link](#))
- [Differential effects of cation-chloride co-transport-blocking diuretics in a rat hippocampal slice model of epilepsy.](#)
The cation-Cl⁻ co-transport-blocking loop diuretics have clinically known... 13th July, 2006
 UCB S.A., CNS Research, B-1420 Braine-l'Alleud, Belgium.- Epilepsy Res. 2006 May;69(2):93-9. Epub 2006 Feb 21. ([DOI Direct Link](#))
- [Solubilization and immunopurification of rat brain synaptic vesicle protein 2A with maintained binding properties.](#)
This study reports the solubilization of the rat synaptic vesicle protein... 11th May, 2006
 UCB S.A., CNS In Vitro Pharmacology, Building R4, Chemin du Foriest,- Neurosci Lett. 2006 May 1;398(1-2):107-12. Epub 2006 Jan 24. ([DOI Direct Link](#))
- [Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction.](#)
RATIONALE: The aim of this review article is to analyse which... 5th May, 2006
 Drug Metabolism and Pharmacokinetics, UCB S.A., 21 rue de Neuilly, 92003- Eur J Clin Pharmacol. 2005 Dec;61(12):863-72. Epub 2005 Nov 24. ([DOI Direct Link](#))
- [Changes in pH differently affect the binding properties of histamine H1 receptor antagonists.](#)
We investigated the effect of acidic pH, a condition that can be... 11th March, 2006
 UCB S.A., In vitro Pharmacology, Building R4, Chemin du Foriest, 1420- Eur J Pharmacol. 2006 Jan 20;530(3):205-14. Epub 2006 Jan 4. ([DOI Direct Link](#))
- [Characterization of \[\(3\)H\]ucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cord.](#)
The novel antiepileptic drug levetiracetam... 14th February, 2006
 UCB S.A., CNS In Vitro Pharmacology, Building R4, Chemin du Foriest,- Eur J Pharmacol. 2005 Sep 27;520(1-3):70-6. ([DOI Direct Link](#))
- [Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines.](#)
The predictive efficacy of drugs in humans is frequently estimated from... 13th December, 2005
 UCB S.A., In Vitro Pharmacology Department, Chemin du Foriest, UCB S.A.,- Inflamm Res. 2005 Sep;54(9):367-9. ([DOI Direct Link](#))
- [Caffeine-induced epileptiform field potentials in rat hippocampal slices: a pharmacological characterization.](#)
Pharmacological modulation of the epileptiform electric activity induced... 14th January, 2005
 Preclinical CNS Research, UCB S.A. Pharma Sector, Chemin du Foriest,- Neuropharmacology. 2004 Nov;47(6):926-34. ([DOI Direct Link](#))
- [Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog.](#)
1: The pharmacokinetics and metabolism of 14C-levetiracetam, a new... 13th November, 2004
 UCB S. A., Pharma Sector, Department of Global Product Safety and- Xenobiotica. 2004 Mar;34(3):281-300. ([DOI Direct Link](#))
- [Is the persistent sodium current a specific target of anti-absence drugs?](#)
The persistent Na⁺ current (INaP) has been proposed as the putative target... 30th June, 2004
 UCB S.A. Pharma Sector, Preclinical CNS Research, Chemin du Foriest,- Neuroreport. 2004 Apr 29;15(6):1049-52.
- [Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. \(S\)-alpha-ethyl-2-oxopyrrolidine acetamide 2 \(levetiracetam, Keppra, UCB...](#) 23rd March, 2004

BioNews Results for UCB S.A.



- [DIARY - Western European Corporate events from Oct 30, 2008](#)
Sharewatch: Oct 30 2008 5:51AM Matching: ucb s
- [UCB's Vimpat Approved By U.S. FDA As Adjunctive Therapy for Partial Onset Seizures in Adults](#)
Pharma Live: Oct 29 2008 3:48PM Matching: ucb s

UCB S.A. Patents:



- 6413970- [Pharmaceutical composition for treating viral diseases](#)
- 6489329- [Pharmaceutical compositions for the treatment of rhinitis](#)
- 6524804- [Process for determining antibiotics containing a .beta.-lactam ring in a biological fluid](#)
- 6624218- [Plasticized polymer compositions](#)
- 6630565- [Phosphorus-comprising materials, their preparation and use](#)
- 6635721- [Powder coating of semicrystalline and amorphous polyesters with crosslinker](#)
- 6660398- [Powder thermosetting compositions for preparing coatings with low gloss finish](#)
- 6686502- [Compounds and methods for treatment of asthma, allergy and inflammatory disorders](#)
- 6699502- [Pharmaceutical compositions for controlled release of active substances](#)
- 6720079- [Polyester containing tertiary carboxyl groups, process for its preparation and thermosetting powder compositions containing it](#)
- 6784197- [2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses](#)
- 6471970- [Use of pharmaceutical compositions capable of being gelled in periodontology](#)
- 6469009- [Pharmaceutical compositions for the treatment of rhinitis](#)
- 6464987- [Pharmaceutical compositions capable of being gelled](#)
- 6417243- [Monomers, oligomers and polymers comprising terminal oxirane groups, their process of preparation and their cationic polymerization under irradiation](#)
- 6420460- [Cationically curable compositions containing triarylcyclopropenyl salts](#)
- 6420602- [Method for the production of tetramethylthiuram disulfide](#)
- 6423842- [Muscarinic agonists and antagonists](#)
- 6432961- [Method for preventing the onset of asthma](#)
- 6436942- [Enantiomers of 1\[\(4-chloro-phenyl\) phenylmethyl\]-4-\[\(4-methylphenyl\) sulfonyl\]piperazine](#)
- 6447899- [Heatsealable multi-layer polymer films](#)
- 6451801- [Compounds and methods for treatment of asthma, allergy and inflammatory disorders](#)
- 6455533- [Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin](#)
- 6461742- [Polyester containing tertiary carboxyl groups, preparation method and thermosetting powder](#)

[compositions containing same](#)

- 6790876- [Radiation curable powder compositions](#)
- 6797713- [Compounds and methods for treatment of asthma, allergy and inflammatory disorders](#)
- 7083807- [Pharmaceutical compositions for the controlled release of active substances](#)
- 7087596- [2-oxo-piperidiny- and 2-oxo-azepanyl alkanic acid derivatives for the treatment of epilepsy and other neurological disorders](#)
- 7090985- [Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases](#)
- 7112612- [N-alkylated GABA compounds, processes for their preparation and their use as medicaments](#)
- 7122682- [Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues](#)
- 7199241- [Process for preparing \(S\) and \(R\)-2-\[4-\(4-chlorobenzhydryl\)piperazin-1-yl\]-ethoxyacetamide](#)
- 7244747- [Imidazole derivatives, processes for preparing them and their uses](#)
- 7358276- [2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses](#)
- 7361668- [Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors](#)
- 7381821- [Piperazine derivatives and their use as synthesis intermediates](#)
- 6977301- [Process for preparing \(S\) and \(R\)-2-\[4-\(4-chlorobenzhydryl\)piperazin-1-yl\]-ethoxyacetamide](#)
- 6969556- [Films, compositions and processes](#)
- 6936633- [Pyrrolidinone derivatives](#)
- 6806287- [2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses](#)
- 6818224- [Use of gellable pharmaceutical compositions in periodontology](#)
- 6818686- [Water based polymer composition comprising a biopolymer and a polymer resin](#)
- 6828328- [Analgesic combination of muscarinic agonists](#)
- 6838536- [Reactive and gel-free compositions for making hybrid composites](#)
- 6884315- [Method for bonding DVD layers](#)
- 6894059- [Compounds and methods for treatment of asthma, allergy and inflammatory disorders](#)
- 6903130- [Pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders](#)
- 6911461- [2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses](#)
- 6916797- [.alpha.-arylethylpiperazine derivatives as neurokinin antagonists](#)
- 7465549- [Methods for identifying agents that bind a levetiracetam binding site \(LBS\) or compete with LEV binding to a LBS of a synaptic vesicle protein 2 \(SV2\)](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

